The United Kingdom and the United States have finalized a important trade agreement that will maintain no import taxes on UK drug shipments going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to boost spending on pharmaceuticals through the public health system. This pledge secures that duties on these crucial exports will be held at zero for a period of three years.
This development comes after previous threats to dramatically increase duties on patented drug imports, with potential rates floated up to double the cost.
"This arrangement between the Britain strengthens the worldwide climate for innovative medicines and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Trade Importance
Drugs are one of the Britain's biggest goods shipped to the United States, which is by far the biggest destination for large UK drugmakers.
Export figures reveal that in the one-year period prior to last September, the UK shipped medicines totaling billions to the US. This figure represented a significant portion of all goods exports in that span.
"This agreement secures employment, boosts investment and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal includes several notable changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to control costs will be capped at 15%. Last year, refunds were more than 20%.
Industry Background
The deal comes amid a protracted row between the drug companies and the UK government over drug pricing and approval rates.
The disagreement were heightened by claims that US consumers were paying significantly more for the same drugs than people in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
